6.25
Precision Biosciences Inc stock is traded at $6.25, with a volume of 162.52K.
It is up +0.81% in the last 24 hours and down -16.33% over the past month.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
See More
Previous Close:
$6.20
Open:
$6.2
24h Volume:
162.52K
Relative Volume:
0.49
Market Cap:
$172.51M
Revenue:
$45.07M
Net Income/Loss:
$-44.49M
P/E Ratio:
-1.6819
EPS:
-3.716
Net Cash Flow:
$-54.23M
1W Performance:
-0.16%
1M Performance:
-16.33%
6M Performance:
-0.16%
1Y Performance:
+10.04%
Precision Biosciences Inc Stock (DTIL) Company Profile
Name
Precision Biosciences Inc
Sector
Industry
Phone
919-314-5512
Address
302 EAST PETTIGREW STREET, DURHAM, NC
Compare DTIL vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
DTIL
Precision Biosciences Inc
|
6.25 | 171.68M | 45.07M | -44.49M | -54.23M | -3.716 |
|
VRTX
Vertex Pharmaceuticals Inc
|
505.64 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
|
MRNA
Moderna Inc
|
196.48 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
REGN
Regeneron Pharmaceuticals Inc
|
742.12 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
928.44 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
200.87 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-30-24 | Initiated | Guggenheim | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Jun-09-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-27-20 | Resumed | BTIG Research | Buy |
| Apr-03-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-05-20 | Initiated | Stifel | Buy |
| Feb-25-20 | Initiated | William Blair | Outperform |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | H.C. Wainwright | Buy |
| Apr-22-19 | Initiated | Barclays | Overweight |
| Apr-22-19 | Initiated | Goldman | Buy |
| Apr-22-19 | Initiated | JP Morgan | Overweight |
| Apr-22-19 | Initiated | Jefferies | Buy |
View All
Precision Biosciences Inc Stock (DTIL) Latest News
Director Stanley Frankel Buys 1,000 Shares of Precision BioSciences (DTIL) - GuruFocus
At $6 per share, a director buys 1,000 Precision Biosciences (DTIL) shares - Stock Titan
Precision BioSciences, Inc. Revenue Breakdown – HAN:PBS0 - TradingView
Form 4 Precision BioSciences Inc For: 29 September By Investing.com - Investing.com Nigeria
Director Melinda Brown Buys 1,135 Shares of Precision BioSciences Inc (DTIL) - GuruFocus
Precision Biosciences director Melinda Brown buys $7,116 in stock By Investing.com - Investing.com Australia
Precision Biosciences director Geno Germano buys $16,384 in stock - Investing.com
Precision Biosciences director Melinda Brown buys $7,116 in stock - Investing.com
Precision Biosciences Director Geno J. Germano Acquires 2,609 Shares at $6.28 Each - kalkinemedia.com
At $6.27 a share, director Melinda Brown buys Precision BioSciences (DTIL) stock. - Stock Titan
A director buys Precision BioSciences (DTIL) shares at $6.28 each, bringing his direct holdings to 47,492. - Stock Titan
How Precision Biosciences Inc. (DTIL) Affects Rotational Strategy Timing - Stock Traders Daily
Precision BioSciences (DTIL) Short Interest & Short Float | Updated Sep 2026 $DTIL - MarketBeat
Precision Biosciences stock holds its Nasdaq listing - AD HOC NEWS
Precision BioSciences, Inc.(NasdaqCM: DTIL) added to S&P Global BMI Index - marketscreener.com
Precision BioSciences stock trades quietly amid lack of fresh catalysts - AD HOC NEWS
Precision BioSciences Inc. (DTIL) Key Financial Ratios – Valuation, Profitability & More - Value Research
Precision BioSciences at H.C. Wainwright conference: two shots on goal By Investing.com - Investing.com Canada
Chronic Hepatitis B Market Statistics Expected to Experience Major Growth by 2034, According to DelveInsight | Gilead Sciences, GlaxoSmithKline, Ionis Pharma, Precision Biosciences, Silverback Thera - Barchart.com
Precision BioSciences, Inc. Share Price Live Today – NASDAQ:DTIL Stock Price, Chart, News, History - upstox.com
CPTx appoints Matt Kane as Chief Financial Officer - GlobeNewswire Inc.
Behavioral Patterns of DTIL and Institutional Flows - Stock Traders Daily
Precision BioSciences stock gains as market cap tops 200 million USD - ad-hoc-news.de
Precision Biosciences Stock Price Forecast. Should You Buy DTIL? - StockInvest.us
Precision BioSciences Inc. (DTIL) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Precision BioSciences Inc. (DTIL) Peer Comparison – Compare with Others - Value Research
DTIL Q2 2026 Earnings: Wider-than-Expected Loss of $1.26 per Share Pressures StockWeak Earnings Momentum - dars.gov.et
iECURE Presents Updated Clinical Data from OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM 2026 - Business Wire
Precision BioSciences doses first patient in DMD gene editing trial By Investing.com - Investing.com Canada
Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study - Yahoo Finance
Precision (DTIL) Momentum: Rises 1.61% to $8.86 in the Current Update; Chart View: the $8.42 to $9.30 Range Remains in Focus for the Current SessionGEX Level - careplusvn.com
Precision (DTIL) Range: Posts a 2.59% Gain to $8.72 at the Close; the Current Price Sits Inside the Supplied Technical Range in the Latest ReadingLiquidity Order Flow - vinanet.vn
DTIL Looks 355.6% Overvalued on GF Value™ - GuruFocus
Precision BioSciences: Promising HBV Editing Evidence (NASDAQ:DTIL) - Seeking Alpha
Precision BioSciences Inc (DTIL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Precision BioSciences Inc Stock Intrinsic Values - GuruFocus
Precision BioSciences Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Precision BioSciences Inc (HAM:PBS0) Competitors 2026 - GuruFocus
Precision BioSciences Inc Stock Warning Signs | HAM:PBS0 - GuruFocus
Who's Buying or Selling Precision BioSciences Inc (HAM:PBS0) Stock Today? - GuruFocus
Precision BioSciences Inc (HAM:PBS0) Stock Price & 30 Year Financial Data - GuruFocus
Precision BioSciences Inc (HAM:PBS0) Stock Earnings Transcripts - GuruFocus
Precision BioSciences Inc (HAM:PBS0) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
HAM:PBS0 Dividend: Does Precision BioSciences Inc Pay a Dividend? - GuruFocus
Precision BioSciences Inc (HAM:PBS0) Stock Price, Trades & News - GuruFocus
Precision BioSciences Inc (HAM:PBS0) Stock News, Headlines & Updates - GuruFocus
Precision BioSciences (DTIL) Rises 1.78% as Gene-Editing Stock Holds Firm Above SupportGrowth Stock Picks - vinanet.vn
Precision BioSciences (DTIL) Advances 1.78% as Gene-Editing Speculation BuildsBear Flag - vinanet.vn
DTIL Q2 2026 Earnings: Wider-than-Expected Loss Pressures SharesEarnings Quality Score - careplusvn.com
DTIL Q2 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage Biotech ChallengesEPS Growth Report - dars.gov.et
Analysts Have Lowered Expectations For Precision BioSciences, Inc. (NASDAQ:DTIL) After Its Latest Results - webull.com
Precision Biosciences Inc Stock (DTIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Precision Biosciences Inc Stock (DTIL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Brown Melinda | Director |
Sep 25 '26 |
Buy |
6.27 |
1,135 |
7,116 |
45,481 |
| Germano Geno J | Director |
Sep 25 '26 |
Buy |
6.28 |
2,609 |
16,385 |
47,492 |
| Amoroso Michael | President and CEO |
Feb 17 '26 |
Option Exercise |
0.00 |
67,797 |
0 |
263,951 |
| Amoroso Michael | President and CEO |
Feb 18 '26 |
Sale |
3.84 |
20,559 |
78,947 |
243,392 |
| Kelly John Alexander | Chief Financial Officer |
Feb 17 '26 |
Option Exercise |
0.00 |
27,584 |
0 |
134,032 |
| Kelly John Alexander | Chief Financial Officer |
Feb 18 '26 |
Sale |
3.84 |
8,149 |
31,292 |
125,883 |
| Scimeca Dario | General Counsel and Secretary |
Feb 17 '26 |
Option Exercise |
0.00 |
16,667 |
0 |
61,382 |
| Scimeca Dario | General Counsel and Secretary |
Feb 18 '26 |
Sale |
3.84 |
4,925 |
18,912 |
56,457 |
| SMITH J. JEFFERSON | Chief Research Officer |
Feb 17 '26 |
Option Exercise |
0.00 |
16,667 |
0 |
126,851 |
| SMITH J. JEFFERSON | Chief Research Officer |
Feb 18 '26 |
Sale |
3.84 |
4,925 |
18,912 |
121,926 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):